OINNet — Online International News Network

GLP-1 weight-loss drugs face stigma, cost and access barriers in South Africa

Widely prescribed obesity treatments show promise but remain complicated by social, economic and medical challenges.

Authenticity Score: 75/100 across 1 source(s). First reported: 2026-11-22T22:10:43Z. Updated: 2026-11-22T22:46:11Z.

GLP-1 receptor agonist drugs, used for weight loss and diabetes management, are gaining traction in South Africa despite significant obstacles. High costs, insurance limitations, social stigma and weight regain after discontinuation complicate patient access and long-term outcomes.

Verified Key Facts

GLP-1 receptor agonist medications, including brands such as Ozempic and Wegovy, are increasingly prescribed for obesity and type 2 diabetes treatment in South Africa. These drugs have demonstrated substantial weight-loss effects and potential cardiovascular benefits, yet their rollout faces multifaceted challenges.

Cost remains a primary barrier, with prices placing treatment out of reach for many patients outside private healthcare. Medical aid schemes and insurers have been criticized for short-term coverage models that do not account for chronic obesity management, often requiring patients to fund ongoing treatment independently.

Social stigma surrounding obesity and pharmacological intervention further complicates uptake, while clinical evidence indicates weight regain is common when patients discontinue the drugs. The intersection of medical efficacy, economic access and societal attitudes continues to shape how these therapies integrate into South Africa's healthcare landscape.

Corroborating Sources